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Abstract
Background: One of the main types of genetic variations in cancer is Copy Number Variations (CNV).
Whole exome sequenicng (WES) is a popular alternative to whole genome sequencing (WGS) to study disease
specific genomic variations. However, finding CNV in Cancer samples using WES data has not been fully
explored.
Results: We present a new method, called CoNVEX, to estimate copy number variation in whole exome
sequencing data. It uses ratio of tumour and matched normal average read depths at each exonic region, to
predict the copy gain or loss. The useful signal produced by WES data will be hindered by the intrinsic noise
present in the data itself. This limits its capacity to be used as a highly reliable CNV detection source. Here, we
propose a method that consists of discrete wavelet transform (DWT) to reduce noise. The identification of copy
number gains/losses of each targeted region is performed by a Hidden Markov Model (HMM).
Conclusion: HMM is frequently used to identify CNV in data produced by various technologies including Array
Comparative Genomic Hybridization (aCGH) and WGS. Here, we propose an HMM to detect CNV in cancer
exome data. We used modified data from 1000 Genomes project to evaluate the performance of the proposed
method. Using these data we have shown that CoNVEX outperforms the existing methods significantly in
terms of precision. Overall, CoNVEX achieved a sensitivity of more than 92% and a precision of more than 50%.
Background
Commercial products of Next Generation Sequencing
(NGS) Technologies such as Roche/454 FLX, Illumina
Genome Analyzer/HiSeq, Applied Biosystems SOLiD™-
System and Helicos Heliscope™have enabled the sequen-
cing of DNA much faster and cheaper than before [1].
These have shifted the paradigm of biological sequence
analysis to a new level. Currently these are not only being
used for the sequencing of whole genome, but also for
sequencing of known exons and transcriptomes as well.
The main motivations behind the technology of targeted
resequencing (TR) include the following among others.
The actual coding regions or the exons of the human
genome account only for ~1% of the total sequences,
which consequently gives about 30 Mb data compared to
3 Gb data in WGS [2]. Currently, getting higher coverage
of targeted regions using NGS technologies is about six
times [3] cheaper and faster compared to achieving the
same coverage of whole genome. On the other hand
approximately 85% of disease causing mutations lie in
the coding regions [4]. Targeted resequencing has been
mainly used in medical sequencing to find disease caus-
ing genetic variations (a review can be found in [5]).
Recent studies on TR and WES data have successfully
detected cancer specific mutations (somatic mutations)
in breast cancer [6-8], ovarian cancer [8] and prostate
cancer [9]. Although, exome sequencing has been suc-
cessfully used to find small variations in cancer genomes,
its potential to find large structural variations such as
CNV has not yet been fully explored.
Cancer arises due to the acquisition of many somatic
variations by the DNA of cancer cells [10]. Copy Number
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Alterations (CNA) play a major part in the progression of
this deadly disease [11]. Until recently, the most common
method to detect CNV in cancer DNA was to use micro
array based technologies. However, during last 2 - 3 years
many algorithms have been developed to identify CNV in
cancerous data generated by whole genome sequencing
[11-15], making use of the vast amount of data produced
by NGS technology. The higher resolution that can be
achieved through NGS data has helped to detect new
variations that were undetectable previously and
include CNVs which are as small as 50 bp [16]. These
methods use the number of reads mapped to a particu-
lar region in the genome, to find copy number varying
regions in one genome compared to one or more
other genomes. Some of these methods have been
adapted from the methods used in aCGH. For example
Circular Binary Segmentation (CBS) [17] and Hidden
Markov Model (HMM) [18]. However, methods in
whole genome sequencing cannot be directly applied
to whole exome sequencing data due to the small size
and sparseness of these data [19]. On the other hand,
the useful signal will be hindered by the intrinsic noise
present in the exome sequencing data itself due to var-
ious biases introduced in target capturing and sequen-
cing phases. To address these issues and to utilize the
advantages provided by targeted resequencing, new
algorithms have to be developed. Since the end of
2011, very few bioinformatics methods for detecting
copy number variations in targeted resequencing data
have been published. The method in [20] describes the
use of TR data to detect CNV in cancer samples. How-
ever, the targeted regions in this method are larger in
size (~ 40 kb), where as exons are much shorter
(200 bp -300 bp). Methods such as [21,22] are devel-
oped to find CNV in non cancerous exome data, such
as in population studies. CONTRA [19] is a recent
method proposed to evaluate cancer TR data using a
pooled or a matched normal sample. ExomeCNV [23]
and Var Scan 2 [24] are specifically designed for whole
exome sequencing of cancer samples. A limitation in
these approaches is that they have a higher number of
false positives which result in a very low precision
(further discussed in Results and discussion section for
ExomeCNV).
In this work, we present CoNVEX, a method that
evaluates exon level depth of coverage ratios to assess
variation in copy number of whole exome capture data
produced from cancer samples. We propose to use Dis-
crete Wavelet Transformation denoising to reduce the
variability of coverage ratios and then use HMM to
detect copy number variations. Our method reduces the
number of false positives by efficient pre-processing of
the data, which results in a mean precision of more
than 50%.
Methods
Data pre-processing
Depth of coverage ratios at each targeted region
Number of reads covering each base at a targeted region is
calculated using BEDTools [25]. Then the exon level
depth of coverage (DOC) is calculated as mean of the per
base coverage of that particular exon. To control the qual-
ity, only the regions having more than 10 bp DOC in the
control sample are retained for further analysis. To correct
for the differences in total number of reads in tumour and
control samples, the exon level DOC is divided by the
mean of DOC of all the exons in that sample. Then the
exon level DOC ratio at region i is calculated as,
Ri =
NTi
NCi
(1)
Where NTi and NCi are the mean normalized DOC of
tumour and control respectively.
DWT smoothing of the data
The actual copy number of the exon regions can be
masked by the noise present in the data itself. This
would lead to lot of false positives. The raw signal of
exon level ratios can be represented as below,
Ri = R¯i + i
Here, R¯i is the true signal of copy number variation with
additive noise, i. This noise can be assumed to be iid with
N(0, s2)where s is the standard deviation of the distribu-
tion. We have used DWT smoothing [26] on Ri, to detect
true signal R¯i to increases the ability of actual copy num-
ber prediction. The DWT smoothing procedure starts by
first taking discrete wavelet transformation of ratios using
“HAAR” wavelet. The fundamental assumption behind
discrete wavelet transform is that, there is a correlation
between the two neighbouring samples or data points.
This is very much true in predicting CNVs as they span
multiple successive exons. The selection of HAAR wavelet
family was based on the fact that it computes the wavelet
coefficients as the difference between two near by blocks
of data points. This feature helps to retain the information
regarding copy number aberration points. The shrinking
of the DWT coefficients were done using soft thresholding
function and the threshold value was calculated by Stein’s
unbiased risk estimator (SURE) for each level of DWT.
Finally, the modified coefficients were used to reconstruct
the de-noised signal at ithlocation of chromosome j, R¯ij , by
taking the inverse transform.
CNV prediction using a Hidden Markov Model
The copy number state for each targeted region is
assigned using a Hidden Markov Model. The copy num-
bers are represented by the hidden states and as default
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we have used states from 0 to 5. These six states can be
interpreted in biological context as homozygous deletion
(copy 0), hemizygous deletion (copy 1), no CNV or copy
neutral (copy 2), 1 copy gain (copy 3), 2, and 3 copy
amplification (copy 4 and 5). DWT smoothed ratios, R¯ij ,
are fed to the model as observations. Each chromosome
j of each tumour-control samples pair is considered
separately for copy number identification using the
HMM. The fitted discrete time HMM is given below
with the same notations as described by Rabiner [27]
and Fridlyand et.al. [18].
1. The total number of hidden states in the model is
given by K and those are denoted by S = S1, S2,...,
SK. If there are L exons in the sample of considera-
tion, the state of lthexon (el) equals to Skwhere 1 ≤ l
≤ L and 1 ≤ k ≤ K.
2. The initial state distribution π = {πk} where
πk = P(e1 = Sk), 1 ≤ k ≤ K
3. The state transition probability distribution A =
ampwhere
amp = P(el+1 = Sp|el = Sm), 1 ≤ m, p ≤ K
4. The emission probability distribution is given by B
= {bk(O)} where
{bk(O)} = N (Ol,μk, σ 2), 1 ≤ l ≤ L and 1 ≤ k ≤ K
Here, N represents the Gaussian distribution. Mean
(μk) of that distribution vary with different states and the
provided normal cell contamination percentage and
ploidy. We used a common standard deviation, s, to all
states.
The above HMM can be represented compactly as l =
(A, B, π) where A, B and π represent transition prob-
ability matrix, emission probability distribution and
initial state distribution. When fitting the above HMM,
the K states must be fixed at first and normal contami-
nation and tumour ploidy must be given as inputs.
The optimal l is selected by optimizing the negative
log-likelihood [27,28]. The initial state distribution π is
chosen such that higher probability is attached to the
most abundantly expected state or the normal state (i.e.
copy 2 in normal humans). Similarly, the transition
probability matrix A, is chosen such that, a higher prob-
ability is assigned to remain in the same state and lower
probability is assigned to transition to another state.
Also the transition to normal state has higher probabil-
ity than transition to a CNV state. Then we used Viterbi
Algorithm to assign the most appropriate copy number
state for each exon.
Relationship between DOC ratio and copy number
Without any imperfections, the normalized ratios
between regional DOC of tumour and control samples(
R¯ij
)
should reflect the relative copy numbers of the
regions in tumour sample compared to control sample.
For example, the ratios (0, 0.5, 1, 1.5, 2) correspond to
the relative copy numbers (0, 1, 2, 3, 4). With no normal
cell admixture and existence of a diploid cancer gen-
ome, these ratios would be the mean of emission distri-
butions that belonged to hidden states of HMM
described above. In the presence of normal cell admix-
ture and anueploidy, the ratios would become,
R¯ij =
αPCij + (1 − α)PTij
PCij
(2)
where a is the normal cell contamination in tumour
cells, PCij is the ploidy of normal cells which equals to 2
in diploid human genome, and PTij is the ploidy of
tumour cells. As proposed by Fidlyand et.al. [18], by
performing median normalization on (2), the ratios will
depend on tumour ploidy only. After performing median
normalization, the ratio is given by
ρij =
αPCij + (1 − α)PTij
PCij
/median
(
αPCij + 1(1 − α)PTij
PCij
)
=
αPCij + (1 − α)PTij
median (αPCij + (1 − α)PTij)
=
αPCij + (1 − α)PTij
PT
(3)
where PT is the most abundant ploidy in the tumour
sample.
Data from 1000 Genome Project
We randomly selected six samples, NA18536, NA18543,
NA18544, NA18548, NA18557, NA18558, from 1000
Genome project, which share some common attributes,
to evaluate the performance of the proposed method.
These selected individuals have been studied by the
HapMap project http://www.hapmap.org. The common
features in these individuals are (i) exome sequencing
was performed by the Beijing Genome Institute, hence a
common exome-capture (NimbleGen V2) has been per-
formed, (ii) male individuals and (iii) from CHB
population.
Simulated data with known copy number variations
We used depth of coverage data at each exon of 1000
Genome samples to simulate CNV. This ensures that
we retain as much intrinsic noise present in non copy
number varying regions. The simulation procedure is as
follows,
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1. First, we retain only the copy number neutral
regions in each sample. The CNV information were
downloaded from the HapMap project genotype file.
2. We selected one sample (NA18536) as the Con-
trol and others as the tumour with known CNV.
3. To do the simulation of gains and losses we ran-
domly selected a region in the Chr 1 and reduce (e.
g: multiplied by 0.05) or amplified (e.g: multiplied by
2) the number of reads in that particular region. For
each variation type, we perform 100 simulations.
4. When we evaluated the performance using only
one sample (NA18543), we used 100 simulations for
each variation type. When we used 5 samples in
simulations, 20 variations were simulated in each
individual sample.
5. To incorporate contamination in the simulation,
we mix the control sample and simulated sample as
per the relationship (a* Control + (1 - a) * Tumor)
where a is the contamination proportion.
Results and discussion
Exon level depth of coverage ratios to detect CNV in
whole exome data
We have used normalized depth of coverage ratios of the
exons among tumour/normal pair to identify the underly-
ing copy number losses and gains. As a quality control
procedure, all the regions in matched normal sample, with
less than an average coverage of 10 are eliminated in both
tumour and normal data sets. However, the useful signal
to be used in CNV detection is depleted by the noise pre-
sent in data itself. This can be attributed to the GC con-
tent bias, mappability, bait capture bias [20] etc. In line
with the observations made in [19], we observed that var-
iation in exon level DOC ratios depends on the average
coverage of both tumour and normal samples (Figure 1A).
This introduces higher variation in ratios in lower cover-
age levels.
Different methods have been proposed to reduce the
experimental biases present in TR data. These include
Figure 1 Exon level coverage ratios before and after smoothing. Exon level coverage ratios among tumour and matched normal samples
(A, C) before DWT smoothing and (B, D) after DWT smoothing. (A, B) show the ratios against the mean log coverage among the two samples.
(C, D) show ratios of chromosome 1 exons against their start locations.
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GC content bias reduction using regression methods
[20,21], taking base level ratios between normal and con-
trol samples [19,23] and bait capture bias reduction using
log transformation [20]. Those methods, adapted from
aCGH or whole genome sequencing based approaches,
try to reduce different experimental biases separately.
Hsu et. al. [29] proposed DWT smoothing as an effective
method to extract true copy number variations from
aCGH data.
In this work, we propose to combine the strengths of
both DWT and HMM to robustly predict copy number
variations in cancer samples. The main novelty of our
approach is the use of DWT smoothing to reduce experi-
mental biases present in whole exome sequencing data
prior to applying a Hidden Markov Model. These experi-
mental biases are modelled here as additive noise to the
true signal. The wavelet coefficients, which are the differ-
ences between two nearby data blocks, can be used to
reduce noise. This is achieved through approximating
some coefficients that do not by pass a certain threshold to
zero. After thresholding step when the inverse transform is
performed on these wavelet coefficients, we can generate a
smoother version of the input signal. Exon level ratios,
before and after DWT smoothing, for data downloaded
from 1000 Genome project (http://www.1000genomes.org)
are given in Figure 1.
After smoothing, we applied an HMM described in
Methods section to detect copy gains and losses. Hidden
Markov Models have been previously used to detect CNV
in exome data (an R package called ExomeCopy) [21], but
not used in this manner to detect CNV in tumour sam-
ples. The differences between ExomeCopy and CoNVEX
are,
• ExomeCopy uses HMM to identify CNVs in male
patients with X-linked Intellectual Disabilities
(XLID)
• They have used depth of coverage of exons as
observations or emissions of hidden states
• The robustness in copy identification is achieved
by pooling coverage data from all patients
Therefore, it fails to identify relative copy number in
cancer samples against a matched normal.
Comparison of the performance of CoNVEX against other
methods
Comparison against ExomeCNV using simulated data
We carried out a comparison between the proposed
method and the existing method, ExomeCNV [23].
Using simulated data, we were able to assess the perfor-
mance of CoNVEX and ExomeCNV for different size
ranges.
A true positive (TP) is identified when the gain or loss of
an exon is correctly identified by the algorithm and a false
positive (FP) identification is defined in the same manner.
When using ExomeCNV, we used their primary CNV
detection method (here after referred to as ExomeCNV1)
and the extension which combines DNACopy [17] (here
after referred to as ExomeCNV2) separately on our simu-
lated data sets. The DNACopy version of ExomeCNV is
applied to make sure that we get results for all exons that
pass the default cut-off level of the coverage (this is a
direction given by the authors of the paper). We used
default parameters given in ExomeCNV R package for
CNV prediction, except for read length and admixture
rate, which we set to 90 and 0.0 in our evaluation.
We used simulated data as described in Methods section
to carry out the comparison. For this, we simulated dele-
tions and duplications in different size ranges. The results
of this evaluation are given in Table 1, 2, 3. Both CoNVEX
and ExomeCNV2 perform better compared to Exo-
meCNV1 in detecting deletions and duplications. This
shows that detecting variations by segmenting the exome
Table 1 Performance of proposed method for 100 simulations.
Type Proposed Method
Sensitivity Specificity Precision Accuracy
Deletions (1 k -1 M bp) 97.82 ± 12.37% 99.94 ± 0.081% 79.25 ± 23.23% 99.94 ± 0.081%
Duplications (1 k -1 M bp) 95.25 ± 19.64% 99.93 ± 0.082% 77.04 ± 26.43% 99.93 ± 0.085%
Performance of CoNVEX in terms of sensitivity, specificity, recall and accuracy. We listed mean and the standard deviation of the each performance measure.
Table 2 Performance of ExomeCNV1 for 100 simulations.
Type ExomeCNV1
Sensitivity Specificity Precision Accuracy
Deletions (1 k - 1 M bp) 97.91 ± 2.81% 86.20 ± 1.57% 8.76 ± 6.54% 86.24 ± 1.56%
Duplications (1 k - 1 M bp) 90.68 ± 9.02% 86.26 ± 1.55% 8.96 ± 8.57% 86.28 ± 1.54%
Performance of ExomeCNV in terms of sensitivity, specificity, recall and accuracy. These results are obtained from running the primary method of ExomeCNV.
Each point indicates mean and standard deviation of the measure.
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works well, rather than only considering one exon at a
time and depicting its copy number when there are large
variations. Another note regarding ExomeCNV1 is that it
doesn’t produce results for about 16% of the exons in the
whole exome.
When compared with ExomeCNV2, our method
showed superior performance in terms of specificity, preci-
sion and accuracy. Slight decrease in sensitivity was
observed in CoNVEX, this is mainly due to the detecting
short variations involving 1 or 2 exons. This can be attrib-
uted to the smoothing step we performed using DWT.
Because of this we separately tested the performance of
CoNVEX for shorter variations sizes as described below.
Both versions of ExomeCNV, showed very poor perfor-
mance when it comes to precision, as it tries to detect as
many as possible variations to maintain a higher sensitivity
rate.
Performance assessment of other methods against CoNVEX
To evaluate the performance of CoNVEX against VarS-
can2 [24], ExomeCopy [21] (uses an HMM to identify
CNV) and CONTRA [19], we used actual genotype of
chromosome 1 in NA18543 individual (test) against
NA18536 individual (control). All methods were run using
their default settings. The results are given in Table 4.
ExomeCopy and CONTRA did not identify any of the
variations present in the test sample. This can be attrib-
uted to the fact that these are specifically designed for
using a background sample [21] or a robust baseline
[19]. VarScan 2 was able to identify the hemizygous
duplication in the region with 60% sensitivity, however
the number of false positives reported by the method
was very high (false positive rate of 32%). CoNVEX
performed well with 90% sensitivity and 0.06% false
positive rate.
Performance of proposed method at different duplication
and deletion sizes
We observed that small deletions or duplications only
span one exon and at most 2 exons due to the sparseness
of the exome data. To evaluate the performance of CoN-
VEX in short variation sizes, we carried out a performance
assessment using simulated data of small deletions and
duplications in chromosome 1 of NA18536 and NA18543
individuals. The results are given in Figure 2.
Median sensitivity of CoNVEX for small variation
detection is 100%. Every deletion of size, more than 200
bp was detected by our method. Hence, giving a mean
sensitivity of 100% for detecting deletions. Mean sensitiv-
ity of detecting each duplication size was more than 85%.
As seen in the graph, almost every variation of size of
more than 800 bases can be detected by the proposed
method. Also, a median precision of more than 30% can
be achieved.
Performance assessment at different levels of
contamination
Normal cell admixture in cancer sample is an issue that
has to be taken into account when predicting copy num-
ber losses and gains. The presence of admixture shrinks
the DOC ratios to 1 (also discussed in Methods). Our
method works on the assumption that the user will pro-
vide the contamination percentage as an input. However,
these data might not be available for every experiment.
Hence, we carried out an evaluation of our method based
on simulated data from NA18543 for two scenarios. First
scenario was to consider the availability of admixture rate
and second was to run the programme without any indi-
cation of contamination. The performance of CoNVEX,
for admixture rates ranging 10% to 70%, in terms of sen-
sitivity, under the first scenario is given in Figure 3A and
the second scenario in Figure 3B. This admixture rate
range is normally present in cancer samples [23]. The
performance of the method drastically reduces after 50%
contamination in scenario 1. However, if proper estima-
tion of admixture rate is provided, we didn’t see much
difference in the performance level of CoNVEX.
Table 3 Performance of ExomeCNV2 for 100 simulations.
Type ExomeCNV2
Sensitivity Specificity Precision Accuracy
Deletions (1 k - 1 M bp) 99.26 ± 2.11% 96.00 ± 1.67% 8.69 ± 6.50% 96.01 ± 1.66%
Duplications (1 k - 1 M bp) 99.98 ± 0.16% 96.06 ± 1.65% 9.62 ± 9.25% 96.08 ± 1.64%
Performance of ExomeCNV in terms of sensitivity, specificity, recall and accuracy. These results are obtained from running the extension of ExomeCNV which
includes DNACopy package. Each point indicates mean and standard deviation of the measure.
Table 4 Performance of CoNVEX against other methods.
Method True positives False positives
CoNVEX 9/10 10/15850
Var Scan2 6/7 4983/15283
ExomeCopy 0/10 9/15850
CONTRA 0/10 0/15847
Table shows the number of exons (numerator) that have been identified as
true positives and false positives by each method. The denominator shows
the total true positives (2ndcolumn) or true negatives (3rdcolumn). Total
number of true negatives differ among methods due to filtering and quality
control done by each of them.
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Conclusions
Exome sequencing data can be used to detect copy
number variations as an initial screening procedure. It is
a cheap and time efficient method. We have successfully
applied the proposed method on exome data to identify
CNVs spanning one to thousands of exons. However,
actual breakpoint of the CNV would not necessarily lie
in the coding region. This limits the use of WES in
identifying actual breakpoints of the CNV.
As discussed in the Results and Discussion section, we
have achieved a higher precision than existing methods
in detecting variations due to the data smoothing step.
However, detection of some of the small variations may
be missed by this smoothing step, as these can be recog-
nised as noise. Further analysis is needed in order to
better detect these variations among higher level of noise.
Although, we have used a matched normal sample to
detect CNVs, the CNV identification can be done based on
a pooled normal sample as described in [19]. This might
give an advantage in finding CNVs in familial studies
assuming all members have a median copy number of two.
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Figure 2 Performance at different variations sizes. Performance of CoNVEX when detecting short variations. Performance is measured by
sensitivity and precision. Both graphs show median (solid lines), 0.1 quantile (dashed lines) and 0.9 quantile (dashed lines) of the results from
100 simulations of (A) duplication and (B) deletions. The solid blue line shows the median sensitivity and the solid red line shows the median
precision. The sizes considered are 200, 400, 600, 800, 1 k, 1.2 k, 1.4 k, 2 k, 5 k and 10 k bases.
Figure 3 Performance of CoNVEX at different admixture rates. The plots show mean sensitivity of CoNVEX at different admixture rates for (A)
duplications and (B) deletions. The dashed red line shows the sensitivity when, user provides the admixture rate as an input. The dashed blue line
shows the sensitivity of the model when it expects zero admixture. The size range of duplications and deletions considered here is 1 k -10 k bp.
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